Olivier Martinez

Bioam Gestion SA (BG) is a venture capital investment firm established in 2000 at the initiative of the French Ministry of Research and located in Paris. The firm invests capital from public and private sources. BG manages FCPR venture capital funds focused on the biotechnology sector. The firm's sponsors include the three French national research institutes: CNRS (fundamental research), INRA (agriculture-oriented research) and INSERM (medical research), as well as financial institutions such as CDC Enterprises, AXA Private Equity, a regional savings bank, and corporations.

Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France.

FAB Pharma SAS operates as a biopharmaceutical company. It develops drugs for the treatment of bacterial infections. It also provides pharmaceutical research services. It focuses on therapeutics addressing current antibiotics resistance issues to control severe bacterial infections. Its products are drugs with low-molecular-weight antibacterial molecules for enzymes in Fatty Acid Biosynthesis I. The company was founded by Stefan Fischer on June 15, 2009 and is headquartered in Paris, France.

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.